Vitality Biopharma, Inc. (VBIO)
EXPM EXPM Primary Summary
Valion Bio Inc. (VBIO) Q1 2026 Earnings Call Prepared Remarks Transcript
Valion Bio Inc. (VBIO) Q1 2026 Earnings Call Prepared Remarks Transcript
Vitality Biopharma, Inc. (VBIO) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Vitality Biopharma, Inc. ever had a stock split?
Vitality Biopharma, Inc. Profile
| Biotechnology Industry | Healthcare Sector | Michael R. Cavanaugh CEO | EXPM Exchange | 92849B107 CUSIP |
| US Country | 52 Employees | - Last Dividend | 7 Mar 2025 Last Split | - IPO Date |
Overview
Vitality Biopharma, Inc. is actively engaged in the development of cannabinoid pharmaceuticals aimed specifically at treating inflammatory disorders within the United States. The company specializes in innovative biopharmaceuticals, leveraging the therapeutic properties of cannabinoids to address various health conditions. One of the primary products currently under development is VBX-100, a tetrahydrocannabinol glycoside, which represents a novel approach towards managing inflammatory bowel disease and irritable bowel syndrome. Vitality Biopharma, Inc. was established in 2007 and has its headquarters located in Los Angeles, California. Notably, the company was previously known as Stevia First Corp. before officially changing its name in July 2016.
Products and Services
- VBX-100
VBX-100 is an oral cannabinoid prodrug specifically designed for the treatment of inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS). This innovative product utilizes tetrahydrocannabinol glycoside to potentially enhance the therapeutic effects while minimizing the psychoactive side effects typically associated with cannabinoid use, thereby offering a novel treatment avenue for patients suffering from these challenging gastrointestinal disorders.
